(Q33500262)

27 July 2017

1 reference

title

Clinical pharmacology of eptifibatide (English)

1 reference

27 July 2017

1 reference

D R Phillips

1

1 reference

27 July 2017

R M Scarborough

series ordinal

2

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 August 1997

1 reference

American Journal of Cardiology

27 July 2017

published in

1 reference

27 July 2017

volume

80

1 reference

27 July 2017

issue

4A

1 reference

27 July 2017

page(s)

11B-20B

1 reference

Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Recognition and treatment of unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Novel antithrombotic therapeutics targeted against platelet glycoprotein IIb/IIIa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Percutaneous transluminal coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Antiplatelet and anticoagulant use after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Platelets and thrombolytic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Platelet membrane glycoproteins: functions in cellular interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

GPIIb-IIIa: the responsive integrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Integrins: versatility, modulation, and signaling in cell adhesion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Calcium binding to human platelet integrin GPIIb/IIIa and to its constituent glycoproteins. Effects of lipids and temperature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Arg-Gly-Asp: a versatile cell recognition signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

EPILOG and CAPTURE trials halted because of positive interim results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Antiplatelet drugs. A comparative review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Extracellular-free Ca++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900572-9

10.1016/S0002-9149(97)00572-9

7 January 2021

Identifiers

DOI

1 reference

27 July 2017

1 reference